Relief Therapeutics and NeuroX Finalize Merger to Form MindMaze Therapeutics

Relief Therapeutics and NeuroX have completed their merger, creating MindMaze Therapeutics Holding SA. This merger combines expertise in precision digital treatments for neurological diseases, aiming to revolutionize neurological care. The company, listed on the SIX Swiss Exchange under the ticker MMTX, integrates digital neurotherapeutics, pharmacological treatments, devices, and an AI platform.

Olaf Blanke, a board member, emphasizes the urgent need for effective neurological treatments due to aging populations. MindMaze seeks to fill existing healthcare gaps with clinically proven treatments from hospital to home care. Walid Hanna, Chairman of the Board, highlighted the innovative foundation of the company, focusing on motor and cognition restoration. The company acquired NeuroX through a share exchange, granting 140 million new shares.